Kemiripan MIS-C Akibat COVID-19 dengan Penyakit Kawasaki pada Anak

Oleh :

dr. Joko Kurniawan, M.Sc., Sp.A

Multisystem Inflammatory Syndrome in Children (MIS-C) pada kasus COVID-19 memiliki beberapa fitur klinis yang menyerupai penyakit Kawasaki. MIS-C adalah kelainan hiperinflamasi dengan keterlibatan multiorgan yang disebabkan oleh severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Kondisi ini telah dilaporkan oleh beberapa negara di seluruh dunia pada kasus infeksi COVID-19 anak.[1,2]

Definisi Multisystem Inflammatory Syndrome in Children (MIS-C) dan Penyakit Kawasaki

Menurut WHO, Multisystem Inflammatory Syndrome in Children (MIS-C) dapat didiagnosis pada anak usia 0-19 tahun yang mengeluhkan demam lebih dari 3 hari, disertai 2 gejala penyerta dan peningkatan penanda inflamasi (seperti LED, CRP, dan prokalsitonin) tanpa adanya penyebab inflamasi lain, serta terbukti mengalami infeksi COVID-19.

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Frenkel LD, Gomez F, Bellanti JA. COVID-19 in children: Pathogenesis and current status. Allergy Asthma Proc. 2021;42(1):8-15.
2. Rajapakse N, Dixit D. Human and novel coronavirus infections in children: a review. Paed Int Child Health. 2020:1-20.
3. Kwak JH, Lee S-Y, Choi J-W. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Cin Exp Pediatr. 2021;64(2):68-75.
4. Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. JCI. 2020;130(11):S942-50.
5. Berardicurti O, Conforti A, Ruscitti P, Cipriani P, Giacomelli R. The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. Exp Rev Clin Immunol. 2020:1-20.
6. Esposito S, Principi N. Multisystem Inflammatory Syndrome in Children Related to SARS‑CoV‑2. Pediatr Drugs. 2020:1-11.
7. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183:968-81.
8. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020:1-11.
9. Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID‐19 and multisystem inflammatory syndrome in children: A systematic review and meta‐analysis. Pediatr Pulmonol. 2020:1-12.
10. Sood M, Sharma S, Sood I, Sharma K, Kaushik A. Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection: a Systematic Review with Meta-analysis. Nature Reviews. 2021:1-10.
11. Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, Bryant B, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. J Pediatr. 2020;226:45-55.
12. Cattalini M, Paolera SD, Zunica F, Bracaglia C, Giangreco M, Verdoni L, et al. Defining Kawasaki disease and pediatric inflammatory multisystem syndrometemporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatr Rheumatol. 2021;19(29):1-11.
13. Yeoa WS, Ng QX. Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. Medical Hypotheses. 2020;144:1-2.
14. Pilania RK, Singh S. Kawasaki Disease. Periodic and Non-Periodic Fevers. 2019;45-63. Published 2019 Oct 30. doi:10.1007/978-3-030-19055-2_4
15. Kiss A, Ryan PM, Mondal T. Management of COVID-19-associated multisystem inflammatory syndrome in children: A comprehensive literature review [published online ahead of print, 2021 Apr 9]. Prog Pediatr Cardiol. 2021;101381. doi:10.1016/j.ppedcard.2021.101381